November 15, 2016 09:58 AM EST
R&D
Pharma

Ab­b­Vie, Enan­ta hep C com­bo looks stel­lar in CKD study as ri­vals hus­tle along the lat­est cures

Arsalan Arif

Founder

There are a va­ri­ety of com­bo ther­a­pies on the mar­ket now that can ef­fec­tive­ly cure the large ma­jor­i­ty of he­pati­tis C cas­es. But over the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times